Review

rabbit anti nuak1 (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech rabbit anti nuak1
Rabbit Anti Nuak1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+nuak1/ARK5+Antibody/bio_rxiv__2025__10__30__685469-147-12-14
Average 93 stars, based on 13 article reviews

rabbit anti nuak1 - by Bioz Stars, 2026-09

93/100 stars

Images

Western Blot:

Article Title: Plasmodium falciparum exploits NUAK1 to establish infection in human erythrocytes
Article Snippet: .. Commercial antibodies used for western blotting include rabbit anti-NUAK1 pThr211 (Kinexus, #PK737), rabbit anti-NUAK1 (Proteintech, #22723-1-AP), mouse anti-MYPT1 (Santa Cruz, #514261), and rabbit anti-GAPDH (Abcam, #ab9485). ..

Image Search Results

Fig. 2 NUAK1 inhibits CD8+ T cell infiltration and activity in HCC. A, B Representative flow cytometry plots showing CD3+, CD8+ and CD8+GZMB+ T cells from Vector, NUAK1-OE, Sh-NC, sh-NUAK1-1#, sh-NUAK1-2# tumors (A) and quantification (B). *p < 0.05, **p < 0.01 compared with vector group, two tailed unpaired t test per group, n = 3; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with sh-NC group; one-way ANOVA, n = 4. C, D Immunofluorescence staining and quantitative statistics of NUAK1 (pink), CD8α (green) and GZMB (red) of tumoral NUAK1 and CD8+ from tumor-grafted mice constructed Vector, NUAK1-OE, sh-NC, sh-NUAK1-1#, sh-NUAK1-2# H22 cells. Scale bars, 50 μm. *p < 0.05, **p < 0.01 compared with vector group, two tailed unpaired t test per group; #p < 0.05, ##p < 0.01 compared with sh-NC group; one-way ANOVA, n = 3

Journal: Molecular medicine (Cambridge, Mass.)

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma.

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: Fig. 2 NUAK1 inhibits CD8+ T cell infiltration and activity in HCC. A, B Representative flow cytometry plots showing CD3+, CD8+ and CD8+GZMB+ T cells from Vector, NUAK1-OE, Sh-NC, sh-NUAK1-1#, sh-NUAK1-2# tumors (A) and quantification (B). *p < 0.05, **p < 0.01 compared with vector group, two tailed unpaired t test per group, n = 3; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with sh-NC group; one-way ANOVA, n = 4. C, D Immunofluorescence staining and quantitative statistics of NUAK1 (pink), CD8α (green) and GZMB (red) of tumoral NUAK1 and CD8+ from tumor-grafted mice constructed Vector, NUAK1-OE, sh-NC, sh-NUAK1-1#, sh-NUAK1-2# H22 cells. Scale bars, 50 μm. *p < 0.05, **p < 0.01 compared with vector group, two tailed unpaired t test per group; #p < 0.05, ##p < 0.01 compared with sh-NC group; one-way ANOVA, n = 3

Article Snippet: Rabbit anti-NUAK1 antibody (4458s, 1:1000 for Western blot), rabbit anti-p-GSK3β antibody (Ser9) (5558T, 1:500 for Western blot; 1:200 for immunohistochemistry), rabbit anti-Lamin B1 (13435 S, 1:500 for western blot) were purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Activity Assay, Flow Cytometry, Plasmid Preparation, Two Tailed Test, Immunofluorescence, Staining, Construct

Fig. 3 NUAK1-mediated tumor immune escape is associated with PD-L1 expression A The expression levels of CD274 mRNA were evaluated in HCC with high (n = 364) and low (n = 364) NUAK1 mRNA expression from the TCGA database. The X axis represents the group with high or low expression of NUAK1, and the Y axis represents the expression level of CD274 mRNA using TPM (Transcripts Per Kilobase of exon model per Million mapped reads). B Correlation analysis of NUAK1 mRNA and of PD-L1 mRNA level in HCC (n = 370) based on the RNA-seq datasets derived from the TCGA database. The X axis represents the expression level of NUAK1 mRNA, and the Y-axis represents the expression level of CD274 mRNA. C Immunohistochemical staining of NUAK1 and PD-L1 in 20 human HCC specimens. Left: Representative images of two tumors. Right: Pearman correlation test between tumoral NUAK1 and PD-L1 IHC scores, note that the scores of some samples overlap. D Representative images of livers from normal and DEN-treated rats. E, F The mRNA (E) and protein (F) expression of NUAK1 and PD-L1 in the livers of normal rats and DEN-tread rats, n = 4. **p < 0.01, ***p < 0.001, two tailed unpaired t test. G IHC staining of tumoral NUAK1 and PD-L1 from tumor-grafted mice constructed with or without NUAK1-OE H22 cells, n = 8. ***p < 0.001, two tailed unpaired t test. H IHC staining of tumoral NUAK1 and PD-L1 from tumor-grafted mice constructed with or without NUAK1-knockdown H22 cells, n = 8. ***p < 0.001, one-way ANOVA

Journal: Molecular medicine (Cambridge, Mass.)

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma.

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: Fig. 3 NUAK1-mediated tumor immune escape is associated with PD-L1 expression A The expression levels of CD274 mRNA were evaluated in HCC with high (n = 364) and low (n = 364) NUAK1 mRNA expression from the TCGA database. The X axis represents the group with high or low expression of NUAK1, and the Y axis represents the expression level of CD274 mRNA using TPM (Transcripts Per Kilobase of exon model per Million mapped reads). B Correlation analysis of NUAK1 mRNA and of PD-L1 mRNA level in HCC (n = 370) based on the RNA-seq datasets derived from the TCGA database. The X axis represents the expression level of NUAK1 mRNA, and the Y-axis represents the expression level of CD274 mRNA. C Immunohistochemical staining of NUAK1 and PD-L1 in 20 human HCC specimens. Left: Representative images of two tumors. Right: Pearman correlation test between tumoral NUAK1 and PD-L1 IHC scores, note that the scores of some samples overlap. D Representative images of livers from normal and DEN-treated rats. E, F The mRNA (E) and protein (F) expression of NUAK1 and PD-L1 in the livers of normal rats and DEN-tread rats, n = 4. **p < 0.01, ***p < 0.001, two tailed unpaired t test. G IHC staining of tumoral NUAK1 and PD-L1 from tumor-grafted mice constructed with or without NUAK1-OE H22 cells, n = 8. ***p < 0.001, two tailed unpaired t test. H IHC staining of tumoral NUAK1 and PD-L1 from tumor-grafted mice constructed with or without NUAK1-knockdown H22 cells, n = 8. ***p < 0.001, one-way ANOVA

Techniques: Expressing, RNA Sequencing, Derivative Assay, Immunohistochemical staining, Staining, Two Tailed Test, Immunohistochemistry, Construct, Knockdown

Fig. 4 NUAK1 promotes PD-L1 expression in HCC cells. A, B The effects of NUAK1 overexpression on the levels of CD274 mRNA (A) and PD-L1 protein (B) in HCC cells, n = 5. **p < 0.01, ***p < 0.001, one-way ANOVA. C, D Effects of NUAK1 knockdown on CD274 mRNA (C) and PD-L1 protein (D) expression in Huh-7 and HepG2 cells, n = 5. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control group; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with sh-NC group; one-way ANOVA

Journal: Molecular medicine (Cambridge, Mass.)

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma.

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: Fig. 4 NUAK1 promotes PD-L1 expression in HCC cells. A, B The effects of NUAK1 overexpression on the levels of CD274 mRNA (A) and PD-L1 protein (B) in HCC cells, n = 5. **p < 0.01, ***p < 0.001, one-way ANOVA. C, D Effects of NUAK1 knockdown on CD274 mRNA (C) and PD-L1 protein (D) expression in Huh-7 and HepG2 cells, n = 5. *p < 0.05, **p < 0.01, ***p < 0.001 compared with control group; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with sh-NC group; one-way ANOVA

Techniques: Expressing, Over Expression, Knockdown, Control

Fig. 7 NUAK1 promotes PD-L1 expression in a GSK3β/β-catenin dependent manner in HCC. A Effects of GSK3β inhibitors SB216763 and LiCl on β-catenin total protein expression in HCC cells. n = 5, ***p < 0.001, one-way ANOVA. B, C Effects of β-catenin knockdown on NUAK1 overexpression-induced CD274 mRNA (B) and PD-L1 protein (C) expression in HCC cells. n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA. D, E Effects of β-catenin overexpression on NUAK1 knockdown-induced CD274 mRNA (D) and PD-L1 protein (E) expression in Huh-7 and HepG2 cells. n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA

Journal: Molecular medicine (Cambridge, Mass.)

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma.

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: Fig. 7 NUAK1 promotes PD-L1 expression in a GSK3β/β-catenin dependent manner in HCC. A Effects of GSK3β inhibitors SB216763 and LiCl on β-catenin total protein expression in HCC cells. n = 5, ***p < 0.001, one-way ANOVA. B, C Effects of β-catenin knockdown on NUAK1 overexpression-induced CD274 mRNA (B) and PD-L1 protein (C) expression in HCC cells. n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA. D, E Effects of β-catenin overexpression on NUAK1 knockdown-induced CD274 mRNA (D) and PD-L1 protein (E) expression in Huh-7 and HepG2 cells. n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA

Techniques: Expressing, Knockdown, Over Expression

Fig. 8 Schematic representation of NUAK1-mediated PD-L1 expression in HCC. NUAK1 enhances the transcriptional expression of PD-L1 by activating the GSK3β/β-catenin signaling pathway, thereby suppressing cytotoxic T cell activity within the tumor microenvironment and facilitating immune evasion in hepatocellular carcinoma

Journal: Molecular medicine (Cambridge, Mass.)

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma.

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: Fig. 8 Schematic representation of NUAK1-mediated PD-L1 expression in HCC. NUAK1 enhances the transcriptional expression of PD-L1 by activating the GSK3β/β-catenin signaling pathway, thereby suppressing cytotoxic T cell activity within the tumor microenvironment and facilitating immune evasion in hepatocellular carcinoma

Techniques: Expressing, Activity Assay

NUAK1 promotes tumor immune escape by inhibiting CD8 + T cell infiltration in HCC. A The expression of NUAK1 in normal ( n = 212) and tumor ( n = 222) tissues in HCC was evaluated based on the GEO database. The X-axis represents normal and HCC (Tumor), and the Y-axis represents the expression level of NUAK1 mRNA. B Kaplan–Meier overall survival curves of HCC ( n = 370, cutoff = 50%) patients with of high and low NUAK1 mRNA expression obtained from the GSE14520. The X-axis represents survival time (months), and the Y-axis represents the patient’s probability of survival. C Correlation analysis of NUAK1 mRNA level and the abundance of CD8 + T cells in HCC ( n = 370) based on the RNA-seq datasets derived from the TCGA database. The X axis represents the expression level of NUAK1 mRNA, and the Y axis represents the abundance of CD8 + T cells. D Immunohistochemical staining of NUAK1 and CD8 + in 20 human HCC specimens. Left: Representative images of two tumors. Scale bar, 50 μm. Right: Pearman correlation test between tumoral NUAK1 and CD8 + IHC scores. Note that the scores of some samples overlap. E Schematic diagram of experimental protocol for survival. F Kaplan-Meier survival curves of vector and NUAK1-overexpression (NUAK1-OE) and sh-vector (sh-NC) and two sh-NUAK1 (1 # and 2 # )-transfected H22 xenografts in BALB/c mice, n = 8 mice per group. G Schematic diagram of experimental protocol for tumor analysis. H Representative images of tumors, quantification of tumor volume and tumor weight collected from vector, NUAK1-OE and sh-NC, two sh-NUAK1 groups, n = 8. ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA. I IHC staining of tumoral NUAK1 and CD8 + from tumor-grafted mice constructed vector or NUAK1-OE H22 cells, n = 8. ** p < 0.01, two tailed unpaired t test per group. J IHC staining of tumoral NUAK1 and CD8 + from tumor-grafted mice constructed sh-NC and two sh-NUAK1 (1 # and 2 # ) H22 cells, n = 8. *** p < 0.001, one-way ANOVA

Journal: Molecular Medicine

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: NUAK1 promotes tumor immune escape by inhibiting CD8 + T cell infiltration in HCC. A The expression of NUAK1 in normal ( n = 212) and tumor ( n = 222) tissues in HCC was evaluated based on the GEO database. The X-axis represents normal and HCC (Tumor), and the Y-axis represents the expression level of NUAK1 mRNA. B Kaplan–Meier overall survival curves of HCC ( n = 370, cutoff = 50%) patients with of high and low NUAK1 mRNA expression obtained from the GSE14520. The X-axis represents survival time (months), and the Y-axis represents the patient’s probability of survival. C Correlation analysis of NUAK1 mRNA level and the abundance of CD8 + T cells in HCC ( n = 370) based on the RNA-seq datasets derived from the TCGA database. The X axis represents the expression level of NUAK1 mRNA, and the Y axis represents the abundance of CD8 + T cells. D Immunohistochemical staining of NUAK1 and CD8 + in 20 human HCC specimens. Left: Representative images of two tumors. Scale bar, 50 μm. Right: Pearman correlation test between tumoral NUAK1 and CD8 + IHC scores. Note that the scores of some samples overlap. E Schematic diagram of experimental protocol for survival. F Kaplan-Meier survival curves of vector and NUAK1-overexpression (NUAK1-OE) and sh-vector (sh-NC) and two sh-NUAK1 (1 # and 2 # )-transfected H22 xenografts in BALB/c mice, n = 8 mice per group. G Schematic diagram of experimental protocol for tumor analysis. H Representative images of tumors, quantification of tumor volume and tumor weight collected from vector, NUAK1-OE and sh-NC, two sh-NUAK1 groups, n = 8. ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA. I IHC staining of tumoral NUAK1 and CD8 + from tumor-grafted mice constructed vector or NUAK1-OE H22 cells, n = 8. ** p < 0.01, two tailed unpaired t test per group. J IHC staining of tumoral NUAK1 and CD8 + from tumor-grafted mice constructed sh-NC and two sh-NUAK1 (1 # and 2 # ) H22 cells, n = 8. *** p < 0.001, one-way ANOVA

Article Snippet: Rabbit anti-β-catenin antibody (66379-1-Ig, 1:1000 for western blot) and rabbit anti-NUAK1 antibody (22723-1-AP, 1:200 for immunofluorescence or immunohistochemistry) were purchased from Protein Tech Group (Chicago, IL, USA).

Techniques: Expressing, RNA Sequencing, Derivative Assay, Immunohistochemical staining, Staining, Plasmid Preparation, Over Expression, Transfection, Immunohistochemistry, Construct, Two Tailed Test

NUAK1 inhibits CD8 + T cell infiltration and activity in HCC. A , B Representative flow cytometry plots showing CD3 + , CD8 + and CD8 + GZMB + T cells from Vector, NUAK1-OE, Sh-NC, sh-NUAK1-1 # , sh-NUAK1-2 # tumors ( A ) and quantification ( B ). * p < 0.05, ** p < 0.01 compared with vector group, two tailed unpaired t test per group, n = 3; # p < 0.05, ## p < 0.01, ### p < 0.001 compared with sh-NC group; one-way ANOVA, n = 4. C , D Immunofluorescence staining and quantitative statistics of NUAK1 (pink), CD8α (green) and GZMB (red) of tumoral NUAK1 and CD8 + from tumor-grafted mice constructed Vector, NUAK1-OE, sh-NC, sh-NUAK1-1 # , sh-NUAK1-2 # H22 cells. Scale bars, 50 μm. * p < 0.05, ** p < 0.01 compared with vector group, two tailed unpaired t test per group; # p < 0.05, ## p < 0.01 compared with sh-NC group; one-way ANOVA, n = 3

Journal: Molecular Medicine

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: NUAK1 inhibits CD8 + T cell infiltration and activity in HCC. A , B Representative flow cytometry plots showing CD3 + , CD8 + and CD8 + GZMB + T cells from Vector, NUAK1-OE, Sh-NC, sh-NUAK1-1 # , sh-NUAK1-2 # tumors ( A ) and quantification ( B ). * p < 0.05, ** p < 0.01 compared with vector group, two tailed unpaired t test per group, n = 3; # p < 0.05, ## p < 0.01, ### p < 0.001 compared with sh-NC group; one-way ANOVA, n = 4. C , D Immunofluorescence staining and quantitative statistics of NUAK1 (pink), CD8α (green) and GZMB (red) of tumoral NUAK1 and CD8 + from tumor-grafted mice constructed Vector, NUAK1-OE, sh-NC, sh-NUAK1-1 # , sh-NUAK1-2 # H22 cells. Scale bars, 50 μm. * p < 0.05, ** p < 0.01 compared with vector group, two tailed unpaired t test per group; # p < 0.05, ## p < 0.01 compared with sh-NC group; one-way ANOVA, n = 3

Techniques: Activity Assay, Flow Cytometry, Plasmid Preparation, Two Tailed Test, Immunofluorescence, Staining, Construct

NUAK1-mediated tumor immune escape is associated with PD-L1 expression A The expression levels of CD274 mRNA were evaluated in HCC with high ( n = 364) and low ( n = 364) NUAK1 mRNA expression from the TCGA database. The X axis represents the group with high or low expression of NUAK1, and the Y axis represents the expression level of CD274 mRNA using TPM (Transcripts Per Kilobase of exon model per Million mapped reads). B Correlation analysis of NUAK1 mRNA and of PD-L1 mRNA level in HCC ( n = 370) based on the RNA-seq datasets derived from the TCGA database. The X axis represents the expression level of NUAK1 mRNA, and the Y-axis represents the expression level of CD274 mRNA. C Immunohistochemical staining of NUAK1 and PD-L1 in 20 human HCC specimens. Left: Representative images of two tumors. Right: Pearman correlation test between tumoral NUAK1 and PD-L1 IHC scores, note that the scores of some samples overlap. D Representative images of livers from normal and DEN-treated rats. E , F The mRNA ( E ) and protein ( F ) expression of NUAK1 and PD-L1 in the livers of normal rats and DEN-tread rats, n = 4. ** p < 0.01, *** p < 0.001, two tailed unpaired t test. G IHC staining of tumoral NUAK1 and PD-L1 from tumor-grafted mice constructed with or without NUAK1-OE H22 cells, n = 8. *** p < 0.001, two tailed unpaired t test. H IHC staining of tumoral NUAK1 and PD-L1 from tumor-grafted mice constructed with or without NUAK1-knockdown H22 cells, n = 8. *** p < 0.001, one-way ANOVA

Journal: Molecular Medicine

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: NUAK1-mediated tumor immune escape is associated with PD-L1 expression A The expression levels of CD274 mRNA were evaluated in HCC with high ( n = 364) and low ( n = 364) NUAK1 mRNA expression from the TCGA database. The X axis represents the group with high or low expression of NUAK1, and the Y axis represents the expression level of CD274 mRNA using TPM (Transcripts Per Kilobase of exon model per Million mapped reads). B Correlation analysis of NUAK1 mRNA and of PD-L1 mRNA level in HCC ( n = 370) based on the RNA-seq datasets derived from the TCGA database. The X axis represents the expression level of NUAK1 mRNA, and the Y-axis represents the expression level of CD274 mRNA. C Immunohistochemical staining of NUAK1 and PD-L1 in 20 human HCC specimens. Left: Representative images of two tumors. Right: Pearman correlation test between tumoral NUAK1 and PD-L1 IHC scores, note that the scores of some samples overlap. D Representative images of livers from normal and DEN-treated rats. E , F The mRNA ( E ) and protein ( F ) expression of NUAK1 and PD-L1 in the livers of normal rats and DEN-tread rats, n = 4. ** p < 0.01, *** p < 0.001, two tailed unpaired t test. G IHC staining of tumoral NUAK1 and PD-L1 from tumor-grafted mice constructed with or without NUAK1-OE H22 cells, n = 8. *** p < 0.001, two tailed unpaired t test. H IHC staining of tumoral NUAK1 and PD-L1 from tumor-grafted mice constructed with or without NUAK1-knockdown H22 cells, n = 8. *** p < 0.001, one-way ANOVA

Techniques: Expressing, RNA Sequencing, Derivative Assay, Immunohistochemical staining, Staining, Two Tailed Test, Immunohistochemistry, Construct, Knockdown

NUAK1 promotes PD-L1 expression in HCC cells. A , B The effects of NUAK1 overexpression on the levels of CD274 mRNA (A) and PD-L1 protein (B) in HCC cells, n = 5. ** p < 0.01, *** p < 0.001, one-way ANOVA. C , D Effects of NUAK1 knockdown on CD274 mRNA (C) and PD-L1 protein (D) expression in Huh-7 and HepG2 cells, n = 5. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with control group; # p < 0.05, ## p < 0.01, ### p < 0.001 compared with sh-NC group; one-way ANOVA

Journal: Molecular Medicine

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: NUAK1 promotes PD-L1 expression in HCC cells. A , B The effects of NUAK1 overexpression on the levels of CD274 mRNA (A) and PD-L1 protein (B) in HCC cells, n = 5. ** p < 0.01, *** p < 0.001, one-way ANOVA. C , D Effects of NUAK1 knockdown on CD274 mRNA (C) and PD-L1 protein (D) expression in Huh-7 and HepG2 cells, n = 5. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with control group; # p < 0.05, ## p < 0.01, ### p < 0.001 compared with sh-NC group; one-way ANOVA

Techniques: Expressing, Over Expression, Knockdown, Control

NUAK1 induces phosphorylation of GSK3β at the Ser9 residue, and inhibition of GSK3β promotes PD-L1 expression in HCC. A Effects of NUAK1 overexpression on the phosphorylation level of GSK3β at Ser 9 in Huh-7 and HepG2 cells, n = 5. ** p < 0.01, *** p < 0.001, one-way ANOVA. B Effects of NUAK1 knockdown on the phosphorylation level of GSK3β at Ser 9 in Huh-7 and HepG2 cells, n = 5. ** p < 0.01, *** p < 0.001 compared with control group; ## p < 0.01, ### p < 0.001 compared with sh-NC group; one-way ANOVA. C IHC staining of tumoral NUAK1 and p-GSK3β from tumor-grafted mice constructed with or without NUAK1-overexpressing H22 cells. Left: Representative images. Scale bar, 50 μm. Right: quantification analysis. n = 8, *** p < 0.001, two tailed unpaired t test. D IHC staining of tumoral NUAK1 and p-GSK3β from tumor-grafted mice constructed with or without NUAK1-knockdown H22 cells. n = 8, *** p < 0.001, one-way ANOVA. E Immunohistochemical staining of NUAK1 and p-GSK3β in 20 human HCC specimens. Left: Representative photos of two tumors. Right: Pearman correlation test between tumoral NUAK1 and p-GSK3β. Note that the scores of some samples overlap. F The protein expression of p-GSK3β in the livers of normal rats and DEN-tread rats ( n = 4). G , H Effects of GSK3β inhibitors SB216763 and lithium chloride (LiCl) on CD274 mRNA ( G ) and PD-L1 protein ( H ) expression in Huh-7 and HepG2 cells. n = 5, *** p < 0.001, one way ANOVA

Journal: Molecular Medicine

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: NUAK1 induces phosphorylation of GSK3β at the Ser9 residue, and inhibition of GSK3β promotes PD-L1 expression in HCC. A Effects of NUAK1 overexpression on the phosphorylation level of GSK3β at Ser 9 in Huh-7 and HepG2 cells, n = 5. ** p < 0.01, *** p < 0.001, one-way ANOVA. B Effects of NUAK1 knockdown on the phosphorylation level of GSK3β at Ser 9 in Huh-7 and HepG2 cells, n = 5. ** p < 0.01, *** p < 0.001 compared with control group; ## p < 0.01, ### p < 0.001 compared with sh-NC group; one-way ANOVA. C IHC staining of tumoral NUAK1 and p-GSK3β from tumor-grafted mice constructed with or without NUAK1-overexpressing H22 cells. Left: Representative images. Scale bar, 50 μm. Right: quantification analysis. n = 8, *** p < 0.001, two tailed unpaired t test. D IHC staining of tumoral NUAK1 and p-GSK3β from tumor-grafted mice constructed with or without NUAK1-knockdown H22 cells. n = 8, *** p < 0.001, one-way ANOVA. E Immunohistochemical staining of NUAK1 and p-GSK3β in 20 human HCC specimens. Left: Representative photos of two tumors. Right: Pearman correlation test between tumoral NUAK1 and p-GSK3β. Note that the scores of some samples overlap. F The protein expression of p-GSK3β in the livers of normal rats and DEN-tread rats ( n = 4). G , H Effects of GSK3β inhibitors SB216763 and lithium chloride (LiCl) on CD274 mRNA ( G ) and PD-L1 protein ( H ) expression in Huh-7 and HepG2 cells. n = 5, *** p < 0.001, one way ANOVA

Techniques: Phospho-proteomics, Residue, Inhibition, Expressing, Over Expression, Knockdown, Control, Immunohistochemistry, Construct, Two Tailed Test, Immunohistochemical staining, Staining

NUAK1 promotes β-catenin expression and nuclear accumulation in HCC A Effects of NUAK1 overexpression on the expression of β-catenin total protein in HCC cells. n = 5, ** p < 0.01, *** p < 0.001, one-way ANOVA. B Effects of NUAK1 knockdown on the β-catenin total protein expression in HCC cells. n = 5, *** p < 0.001 compared with Ctrl group; ## p < 0.01, ### p < 0.001 compared with sh-NC group; one-way ANOVA. C IHC staining of tumoral NUAK1 and β-catenin from tumor-grafted mice constructed with or without NUAK1-overexpressing H22 cells. n = 8, * p < 0.05, two tailed unpaired t test. D IHC staining of tumoral NUAK1 and β-catenin from tumor-grafted mice constructed with or without NUAK1-knockdown H22 cells. Data were expressed by mean ± SEM ( n = 8). * p < 0.05, two-tailed unpaired t test. E Pearman correlation test between tumoral NUAK1 and p-GSK3β in 20 human HCC specimens. Note that the scores of some samples overlap. F The protein expression of β-catenin in the livers of normal rats and DEN-tread rats ( n = 4). G Effects of NUAK1 overexpression on the β-catenin nuclear protein expression in Huh-7 and HepG2 cells. Lamin B1 was used as internal control. n = 5, *** p < 0.001, two-tailed unpaired t test. H Effects of NUAK1 knockdown on the β-catenin nuclear protein expression in Huh-7 and HepG2 cells. Lamin B1 was used as internal control. Data were expressed by mean ± SEM ( n = 5). *** p < 0.001; one-way ANOVA. I Immunofluorescence staining of β-catenin in Huh-7 cells stably transfected with vector, NUAK1-overexpression (NUAK1-OE), sh-Vector (sh-NC), NUAK1-knockdown # 1 (sh-NUAK1 # 1) and NUAK1-knockdown # 2 (sh-NUAK1 # 2) groups

Journal: Molecular Medicine

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: NUAK1 promotes β-catenin expression and nuclear accumulation in HCC A Effects of NUAK1 overexpression on the expression of β-catenin total protein in HCC cells. n = 5, ** p < 0.01, *** p < 0.001, one-way ANOVA. B Effects of NUAK1 knockdown on the β-catenin total protein expression in HCC cells. n = 5, *** p < 0.001 compared with Ctrl group; ## p < 0.01, ### p < 0.001 compared with sh-NC group; one-way ANOVA. C IHC staining of tumoral NUAK1 and β-catenin from tumor-grafted mice constructed with or without NUAK1-overexpressing H22 cells. n = 8, * p < 0.05, two tailed unpaired t test. D IHC staining of tumoral NUAK1 and β-catenin from tumor-grafted mice constructed with or without NUAK1-knockdown H22 cells. Data were expressed by mean ± SEM ( n = 8). * p < 0.05, two-tailed unpaired t test. E Pearman correlation test between tumoral NUAK1 and p-GSK3β in 20 human HCC specimens. Note that the scores of some samples overlap. F The protein expression of β-catenin in the livers of normal rats and DEN-tread rats ( n = 4). G Effects of NUAK1 overexpression on the β-catenin nuclear protein expression in Huh-7 and HepG2 cells. Lamin B1 was used as internal control. n = 5, *** p < 0.001, two-tailed unpaired t test. H Effects of NUAK1 knockdown on the β-catenin nuclear protein expression in Huh-7 and HepG2 cells. Lamin B1 was used as internal control. Data were expressed by mean ± SEM ( n = 5). *** p < 0.001; one-way ANOVA. I Immunofluorescence staining of β-catenin in Huh-7 cells stably transfected with vector, NUAK1-overexpression (NUAK1-OE), sh-Vector (sh-NC), NUAK1-knockdown # 1 (sh-NUAK1 # 1) and NUAK1-knockdown # 2 (sh-NUAK1 # 2) groups

Techniques: Expressing, Over Expression, Knockdown, Immunohistochemistry, Construct, Two Tailed Test, Control, Immunofluorescence, Staining, Stable Transfection, Transfection, Plasmid Preparation

NUAK1 promotes PD-L1 expression in a GSK3β/β-catenin dependent manner in HCC. A Effects of GSK3β inhibitors SB216763 and LiCl on β-catenin total protein expression in HCC cells. n = 5, *** p < 0.001, one-way ANOVA. B , C Effects of β-catenin knockdown on NUAK1 overexpression-induced CD274 mRNA ( B ) and PD-L1 protein ( C ) expression in HCC cells. n = 5, * p < 0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA. D , E Effects of β-catenin overexpression on NUAK1 knockdown-induced CD274 mRNA ( D ) and PD-L1 protein ( E ) expression in Huh-7 and HepG2 cells. n = 5, * p < 0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA

Journal: Molecular Medicine

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: NUAK1 promotes PD-L1 expression in a GSK3β/β-catenin dependent manner in HCC. A Effects of GSK3β inhibitors SB216763 and LiCl on β-catenin total protein expression in HCC cells. n = 5, *** p < 0.001, one-way ANOVA. B , C Effects of β-catenin knockdown on NUAK1 overexpression-induced CD274 mRNA ( B ) and PD-L1 protein ( C ) expression in HCC cells. n = 5, * p < 0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA. D , E Effects of β-catenin overexpression on NUAK1 knockdown-induced CD274 mRNA ( D ) and PD-L1 protein ( E ) expression in Huh-7 and HepG2 cells. n = 5, * p < 0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA

Techniques: Expressing, Knockdown, Over Expression

Schematic representation of NUAK1-mediated PD-L1 expression in HCC. NUAK1 enhances the transcriptional expression of PD-L1 by activating the GSK3β/β-catenin signaling pathway, thereby suppressing cytotoxic T cell activity within the tumor microenvironment and facilitating immune evasion in hepatocellular carcinoma

Journal: Molecular Medicine

Article Title: NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma

doi: 10.1186/s10020-025-01088-7

Figure Lengend Snippet: Schematic representation of NUAK1-mediated PD-L1 expression in HCC. NUAK1 enhances the transcriptional expression of PD-L1 by activating the GSK3β/β-catenin signaling pathway, thereby suppressing cytotoxic T cell activity within the tumor microenvironment and facilitating immune evasion in hepatocellular carcinoma

Techniques: Expressing, Activity Assay

Review

rabbit anti nuak1 (Proteintech)

Structured Review

Images

Related Articles

Western Blot:

Similar Products

Image Search Results